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Objectives To propose standardized consensus deﬁnitions for important clinical endpoints in transcatheter aortic valve implan-
tation (TAVI), investigations in an effort to improve the quality of clinical research and to enable meaningful compari-
sons between clinical trials. To make these consensus deﬁnitions accessible to all stakeholders in TAVI clinical
research through a peer reviewed publication, on behalf of the public health.
Background Transcatheter aortic valve implantation may provide a worthwhile less invasive treatment in many patients with severe
aortic stenosis and sinceits introductionto the medical community in2002, there hasbeen an explosivegrowthinpro-
cedures.TheintegrationofTAVIintodailyclinicalpracticeshouldbeguidedbyacademicactivities,whichrequiresahar-
monized and structured process for data collection, interpretation, and reporting during well-conducted clinical trials.
Methods
and results
The Valve Academic Research Consortium established an independent collaboration between Academic Research
organizations and specialty societies (cardiology and cardiac surgery) in the USA and Europe. Two meetings, in
San Francisco, California (September 2009) and in Amsterdam, the Netherlands (December 2009), including key
physician experts, and representatives from the US Food and Drug Administration (FDA) and device manufacturers,
were focused on creating consistent endpoint deﬁnitions and consensus recommendations for implementation in
TAVI clinical research programs. Important considerations in developing endpoint deﬁnitions included (i) respect
for the historical legacy of surgical valve guidelines; (ii) identiﬁcation of pathophysiological mechanisms associated
with clinical events; (iii) emphasis on clinical relevance. Consensus criteria were developed for the following end-
points: mortality, myocardial infarction, stroke, bleeding, acute kidney injury, vascular complications, and prosthetic
valve performance. Composite endpoints for TAVI safety and effectiveness were also recommended.
Conclusion Although consensus criteria will invariably include certain arbitrary features, an organized multidisciplinary process to
develop speciﬁc deﬁnitions for TAVI clinical research should provide consistency across studies that can facilitate the
†The Valve Academic Research Consortium (VARC) consists of representatives from several independent Academic Research Organizations, several Surgery and Cardiology
Societies, members of the U.S. Food and Drug Administration, and several independent experts (Appendices 1 and 2).
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described in this document may be useful for regulatory and clinical trial purposes.
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Introduction
Since the introduction of transcatheter aortic valve implantation
(TAVI) in 2002
1, there has been increasing interest in the ﬁeld of
catheter-based treatment of high-surgical-risk patients with symp-
tomatic aortic stenosis (AS).
2–7 Introduction of this new technol-
ogy should ideally follow the standard bench-to-bedside
evidence-based medicine pattern, starting with pre-clinical testing
and advancing to clinical investigations. Unfortunately, the explo-
sive growth of TAVI (Figure 1) has created a ‘clinical data conun-
drum’: investigators were not prepared to optimally organize and
interpret clinical data for this radically different treatment, render-
ing thoughtful assessment of clinical trial outcomes difﬁcult and
inter-study results comparisons problematic.
8–11
Surgical valve clinical research guidelines have been developed
using a more traditional ‘multi-society approach’, have been
revised approximately every 10 years, incorporate not merely clini-
cal endpoints but also issues such as structural valve deterioration
and non-structural valve dysfunction, and often divide clinical
events into those that are valve and non-valve related.
12 Interven-
tional cardiology has a tradition of agreed upon clinical endpoint
deﬁnitions and clinical trial methodologies
13,14 and recently has
incorporated a consensus process to standardize key endpoint
deﬁnitions by convening an Academic Research Consortium
(ARC) among Academic Research Organizations (AROs) from
the USA and Europe joined by representatives from the USFDA
and device manufacturers.
14 The ARC process demonstrated the
power of a well-managed international goal-directed academic
consortium collaborating effectively with the FDA and industry
to establish consensus clinical endpoint deﬁnitions and to
improve the conduct of clinical research.
In the spirit of the ARC-mission statement,
14 the ‘Valve Aca-
demic Research Consortium’ (VARC) was organized as an
amalgam of the ARO and multi-society guideline models with
strong participation from independent experts, the FDA, and
medical device manufacturers (Appendices 1 and 2). Two
in-person meetings on 19 September 2009 in San Francisco, CA
and on 5–6 December 2009 in Amsterdam, the Netherlands,
involving VARC study group members and invited guests (including
the FDA and industry representatives) provided much of the sub-
stantive discussion from which this consensus manuscript was
derived.
The goals of VARC are to combine the expertise of surgeons,
interventionalists, medical cardiologists, clinical trialists, and
other specialists (representing relevant disciplines including echo-
cardiography, vascular medicine, and neurology) to arrive at a
consensus for (i) selecting appropriate clinical endpoints reﬂecting
device, procedure and patient-related effectiveness and safety,
and (ii) standardizing deﬁnitions for single and composite clinical
endpoints.
Importantly, this ﬁrst consensus manuscript was not intended as
a ‘guidelines statement’ or a ‘guidance document’, but rather
should be viewed as a roadmap to facilitate the standardization
of future TAVI and other aortic valve clinical research
Figure 1 Current generation transcatheter aortic valve therapies. (A) balloon-expandable, stainless steel support structure, bovine pericardial
valve; (B) self-expanding, nitinol support structure, porcine pericardial valve.
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deﬁning clinical endpoints for
transcatheter aortic valve
implantation investigations:
general considerations
Criteria for endpoint deﬁnitions
The deﬁnitions of major clinical endpoints must follow a multi-step
thought process.
† Each major endpoint should address issues that establish either
the safety and/or the effectiveness of the proposed new therapy.
– Safety is characterized by the avoidance of device-related or
procedural complications.
– Effectiveness is a more complex descriptor, as it encompasses
both the avoidance of negative disease-related outcomes and
objective measures of clinical functional beneﬁt.
† The endpoints should relate short- and long-term pathophysiolo-
gical mechanisms to meaningful clinical events.
† Endpoint deﬁnitions must be consistent with the body of pub-
lished literature, but still reﬂect unique or evolving aspects of
the new therapy.
† The emphasis should be on deﬁnitions that accurately represent
essential patient-oriented clinical outcomes.
† The endpoints must be well deﬁned (preferably through blinded
adjudication processes) such that they can be to be subjected to
statistical analysis.
It is helpful to reference a standardized deﬁnition format regarding
(i) the speciﬁc treatment, (ii) the place of occurrence, (iii) the time
of occurrence, and (iv) the speciﬁc type of endpoint.
Device, procedure, and patient-oriented
outcomes
Endpoint deﬁnitions for TAVI will in most cases be characterized in
relation to the speciﬁc implant device, the implant procedure, and
the resultant patient-oriented outcomes, which can occur at any
time after the procedure. During the early phases of therapy devel-
opment, particular attention must be directed to the safety and
performance of the device. Therefore, VARC tries to strike a com-
promise by also elucidating device and procedure-related events,
which are essential to the understanding of a new class of catheter-
based therapies.
Since TAVI is fundamentally the placement of a prosthetic aortic
valve and will be compared with surgical aortic valve replacement
(AVR), tradition should be respected and crucial endpoints such as
all-cause mortality and device durability must be assessed longitud-
inally for the life of the implant.
12 However, primary clinical end-
points used in pivotal clinical trials for regulatory approval of
TAVI devices should incorporate a shorter time domain of 1 to
2 years after the index procedure. These recommended shorter
time horizons should not discourage the standard long-term
follow-up procedures for prosthetic heart valves.
Proposed safety and efﬁcacy
endpoints
Mortality
All-cause mortality in surgical clinical trials has become the ‘gold
standard’ in previously published consensus and guideline docu-
ments.
12 The advantage of reporting all-cause mortality is that it
is both objective (without bias) and pragmatic from the standpoint
of ascertainment and adjudication. However, the use of all-cause
mortality in high-risk TAVI patients may be misleading, resulting
in disproportionate reporting of mortal events unrelated to
either the treatment device or the procedure. Therefore, VARC
proposes to use all-cause mortality as a primary clinical endpoint,
but also recommends further subdivision of mortality, speciﬁcally
denoting cardiovascular mortality as an important secondary end-
point (Table 1). Of note, ‘unknown’ deaths should be considered
as cardiovascular in origin and to improve the ascertainment of
death, the social security death index or national death registries
should be utilized in cases of patients lost to follow-up.
Consistent with surgical guidelines and surgical clinical trial
practices,
12 mortality should be formally assessed and reported
at 30 days after the index procedure (or longer if the patient
was not discharged from the treatment hospital or a secondary
convalescent facility). Since there may be either unknown or
under-reporting of early device failure modes, a more appropriate
duration for all-cause mortality as a primary endpoint in TAVI
clinical trials is 1 year after the index procedure. After 1 year,
mortality should be recorded at yearly intervals for a minimum
of 5 years, or ideally, for the duration of the prosthetic valve
implant, in the form of well-deﬁned post-approval surveillance
registries.
Myocardial infarction
In 2007, the joint ESC/ACC/AHA/WHF task force for the redeﬁni-
tion of Myocardial infarction (MI) established diagnostic criteria
and updated guidelines for a universal MI deﬁnition to be used in
clinical trials.
13 This universal MI deﬁnition is highly sensitive,
relying heavily on the measurement of cardiac biomarkers (prefer-
ably troponin). Conversely, surgical valve guidelines have adopted a
................................................................................
Table 1 Mortality
Cardiovascular mortality
Any one of the following criteria:
Any death due to proximate cardiac cause (e.g. MI, cardiac
tamponade, worsening heart failure)
Unwitnessed death and death of unknown cause
All procedure-related deaths, including those related to a
complication of the procedure or treatment for a complication
of the procedure
Death caused by non-coronary vascular conditions such as
crebrovascular disease, pulmonary embolism, ruptured aortic
aneurysm, dissecting aneurysm, or other vascular disease
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diagnoses and excluding both intra-operative and post-operative
MIs, unless the MI was caused by a coronary embolus.
12
Valve Academic Research Consortium proposes a more ‘cen-
trist’ approach to MI deﬁnitions after TAVI, recognizing that
many patients have coexistent aortic valve and coronary artery
disease,
15 which requires an MI deﬁnition that does not
exclude peri-procedural or late MIs that may impact patient out-
comes. Valve Academic Research Consortium proposes to deﬁne
peri-procedural MI as an acute ischaemic event that is associated
with documented and clinically signiﬁcant myocardial necrosis
(Table 2). This deﬁnition does not include ischaemic events
after TAVI or surgery deﬁned solely by biomarker elevations
without a clinically evident ischaemic insult. Since troponin
measurements are an extremely sensitive biomarker of myocar-
dial necrosis, VARC recommends that CPK-MB should be the
peri-procedural biomarker of choice in TAVI clinical trials. Bio-
marker samples ideally should be obtained at baseline, twice
after the procedure (separated by at least 6 h), and if still elev-
ated, daily thereafter until values are declining. Since TAVI may
involve open surgical procedures (e.g. transapical access), the bio-
marker diagnosis of peri-procedural MI requires a .20% increase
in the second post-procedure sample and a threshold elevation
of ten times the upper normal range. An electrocardiogram
should be collected at baseline and at least once after the pro-
cedure prior to discharge to document the presence or
absence of new Q-waves. The peri-procedural interval is inclusive
of all events that begin within 72 h of the index procedure. Acute
ischaemic events occurring after 72 h are considered spontaneous
MIs and are deﬁned in accordance with the universal MI guide-
lines,
13 as further modiﬁed by ARC
14 (Table 2). Finally, a con-
ﬁrmed coronary embolus, occurring at any time, should be
reported as an independent event, if biomarker changes and
associated ﬁndings fulﬁl deﬁnition criteria.
Stroke
Recently, two reports have indicated a high frequency of new per-
fusion abnormalities (presumably embolic) detected by diffusion-
weighted magnetic resonance imaging (MRI) studies soon after
TAVI,
16,17 although the clinical signiﬁcance of these early perfusion
defects remains unclear. Strokes during and after TAVI may occur
due to embolic events from multiple sources, procedure-related
aortic dissections, ischaemia from hypotension, or haemorrhagic
complications associated with adjunctive pharmacotherapy. Insights
on stroke deﬁnitions are in a state of evolution and VARC examined
viewpoints derived from several sources, including recent multi-
society consensus documents
12,18,19 and multi-center randomized
trials, in which stroke was an important endpoint.
20–29 Valve Aca-
demicResearchConsortiumconsideredﬁveimportantissuesinarriv-
ing at clinically relevant stroke deﬁnitions, as follows: (i) a clinical
diagnosis of stroke which ruled out metabolic or toxic encephalopa-
thy, pharmacological inﬂuences, and non-central neurological symp-
toms, (ii) the role of neuroimaging studies for conﬁrmation of the
diagnosis, (iii) the distinction of stroke vs. transient ischaemic attack
(TIA) (including timing), (iv) categorization of stroke into major and
minor events based on the degree of disability as deﬁned by conven-
tional neurological assessment tools, and (v) sub-classiﬁcation of
strokes into haemorrhagic, ischaemic, and undetermined categories.
Table 3 outlines the diagnostic criteria and speciﬁc deﬁnitions for
TIA and stroke as proposed by VARC. There is growing accep-
tance that neuroimaging is an important biomarker for the diagno-
sis of neuronal injury and stroke
18,19 and diffusion-weighted MRI is
generally considered the procedure of choice in the context of
acute neurological syndromes.
30 If a stroke is reported without evi-
dence of conﬁrmation of the diagnosis by the methods outlined in
Table 3, the event may still be considered a stroke on the basis of
the clinical presentation alone, but formal adjudication by qualiﬁed
neurologists who are members of, or consultants to, a clinical
events committee is mandatory. Patients with a global encephalo-
pathy will not be reported as a stroke without unequivocal neuroi-
maging ﬁndings. Diagnosis of stroke in patients with a previously
documented neurological deﬁcit is more problematic and requires
clinical assessment by a neurologist accompanied by appropriate
new CT or MRI ﬁndings. In patients with a previous stroke and per-
sistent neurological deﬁcits, baseline pre-treatment neurological
consultation and neuroimaging studies are recommended.
The earliest time of new neurological symptoms is deﬁned as
the time of onset of the stroke or TIA. When a patient awakens
or begins responding (if previously unconscious) after the index
................................................................................
Table 2 Myocardial infarction
Peri-procedural MI (≤72 h After the index procedure)
New ischaemic symptoms (e.g. chest pain or shortness of breath),
or new ischaemic signs (e.g. ventricular arrhythmias, new or
worsening heart failure, new ST-segment changes,
haemodynamic instability, or imaging evidence of new loss of
viable myocardium or new wall motion abnormality),
AND
Elevated cardiac biomarkers (preferably CK-MB) within 72 h after
the index procedure, consisting of two or more post-procedure
samplesthat are .6–8 h apartwith a 20% increase in the second
sampleand a peak valueexceeding10x the 99thpercentile upper
reference limit (URL), or a peak value exceeding 5x the 99th
percentile URL with new pathological Q waves in at least two
contiguous leads.
Spontaneous MI (.72 h after the index procedure)
Any one of the following criteria:
Detection of rise and/or fall of cardiac biomarkers (preferably
troponin) with at least one value above the 99th percentile URL,
together with evidence of myocardial ischaemia with at least one
of the following:
ECG changes indicative of new ischaemia [new ST-T changes or
new left bundle branch block (LBBB)]
New pathological Q waves in at least two contiguous leads
Imaging evidence of new loss of viable myocardium or new wall
motion abnormality
Sudden, unexpected cardiac death, involving cardiac arrest, often
with symptoms suggestive of myocardial ischaemia, and
accompanied by presumably new ST elevation, or new LBBB,
and/or evidence of fresh thrombus by coronary angiography and/
or at autopsy, but death occurring before blood samples could
be obtained, or at a time before the appearance of cardiac
biomarkers in the blood.
Pathological ﬁndings of an acute myocardial infarction.
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stroke or TIA is considered to have occurred during the index pro-
cedure. The diagnosis of a transient ischemic attack is deﬁned as
complete resolution of new neurological symptoms usually
within 1–2 h but always within 24 h and also requires a normal
neuroimaging study.
18,19 A stroke fulﬁling the diagnostic criteria
in Table 3 is classiﬁed as a major stroke based upon ongoing signiﬁ-
cant clinical disability, deﬁned as a Modiﬁed Rankin Score ≥2.
Although the initial Modiﬁed Rankin Score should be recorded
after 7 days or at the time of hospital discharge, the attribution
of clinically signiﬁcant disability requires a Modiﬁed Rankin Score
≥2 at both 30 and 90 days follow-up (allowing sufﬁcient time
for stroke disability to stabilize). The Modiﬁed Rankin Score deter-
minations should be performed by qualiﬁed individuals who have
undergone a certiﬁcation process.
31–34 A minor stroke must also
fulﬁl stroke diagnostic criteria, with either resolution of new
neurological symptoms within 24 h or persistence of symptoms
.24 h and a Modiﬁed Rankin Score ,2 at both 30 and 90 days
follow-up. If there is discordance between the 30 and 90-day
Modiﬁed Rankin Scores, the ﬁnal determination of major vs.
minor strokes should be adjudicated by the neurology members
of the clinical events committee. For the purposes of clinical trial
endpoints, VARC advocates that only major strokes should be con-
sidered as an important safety endpoint, however, all neurological
events should be reported as adverse events.
Stroke will be further stratiﬁed into ischaemic, haemorrhagic, or
undetermined origin utilizing newly proposed deﬁnitions by an
FDA consensus panel.
35 Ischaemic stroke is as an acute sympto-
matic episode of focal cerebral, spinal, or retinal dysfunction
caused by an infarction of central nervous system tissue. Haemor-
rhagic stroke is an acute symptomatic episode of focal or global
cerebral or spinal dysfunction caused by a non-traumatic intrapar-
enchymal, intraventricular, or subarachnoid haemorrhage. An
undetermined stroke is a stroke with insufﬁcient information to
allow categorization as either of ischaemic or haemorrhagic origin.
Bleeding complications
Bleeding is a critical safety endpoint in evaluating contemporary
pharmacological agents and interventional devices.
36–44 Valve Aca-
demic Research Consortium carefully reviewed several literature
sources including (i) landmark clinical trials assessing the effects
of anti-thrombotic medications in stable and acute coronary syn-
dromes,
45–59 (ii) a report by the Control of Anticoagulation Sub-
committee of the International Society on Thrombosis and
Haemostasis,
60 and (iii) surgery guidelines after cardiac valve
procedures.
12
The deﬁnition of clinically meaningful bleeding was guided by the
following principles: (i) the deﬁnition must be based on objective
criteria, including an obvious source of bleeding or number of
transfusions; (ii) serious or meaningful bleeding must result in
death, be life-threatening, be proven to be associated with
................................................................................
................................................................................
Table 4 Bleeding
Life-threatening or disabling bleeding
Fatal bleeding OR
Bleeding in a critical area or organ, such as intracranial, intraspinal,
intraocular, or pericardial necessitating pericardiocentesis, or
intramuscular with compartment syndrome OR
Bleeding causing hypovolemic shock or severe hypotension
requiring vasopressors or surgery OR
Overt source of bleeding with drop in haemoglobin of ≥5 g/dL or
whole blood or packed red blood cells (RBCs) transfusion ≥4
units
a
Major bleeding
Overt bleeding either associated with a drop in the haemoglobin
level of at least 3.0 g/dL or requiring transfusion of two or three
units of whole blood/RBC AND
Does not meet criteria of life-threatening or disabling bleeding
Minor Bleeding
Any bleeding worthy of clinical mention (e.g. access site
haematoma) that does not qualify as life-threatening, disabling or
major
aGiven one unit of packed RBC typically will raise blood haemoglobin
concentration by 1 g/dL, an estimated decrease in haemoglobin will be calculated.
................................................................................
Table 3 Stroke
Stroke diagnostic criteria
Rapid onset of a focal or global neurological deﬁcit with at least one
of the following: change in level of consciousness, hemiplegia,
hemiparesis, numbness or sensory loss affecting one side of the
body, dysphasia or aphasia, haemianopia, amaurosis fugax, or
other neurological signs or symptoms consistent with stroke
Duration of a focal or global neurological deﬁcit ≥24 h; OR , 24 h,
if therapeutic intervention(s) were performed (e.g. thrombolytic
therapy or intracranial angioplasty); OR available neuroimaging
documents a new haemorrhage or infarct; OR the neurological
deﬁcit results in death
No other readily identiﬁable non-stroke cause for the clinical
presentation (e.g. brain tumour, trauma, infection,
hypoglycaemia, peripheral lesion, pharmacological inﬂuences)
a
Conﬁrmation of the diagnosis by at least one of the following:
Neurology or neurosurgical specialist
Neuroimaging procedure (MR or CT scan or cerebral
angiography)
Lumbar puncture (i.e. spinal ﬂuid analysis diagnostic of
intracranial haemorrhage)
Stroke deﬁnitions
Transient ischaemic attack:
New focal neurological deﬁcit with rapid symptom resolution
(usually 1–2 h), always within 24 h
Neuroimaging without tissue injury
Stroke: (diagnosis as above, preferably with positive neuroimaging
study)
Minor—Modiﬁed Rankin score ,2 at 30 and 90 days
b
Major—Modiﬁed Rankin score ≥2 at 30 and 90 days
aPatients with non-focal global encephalopathy will not be reported as a stroke
without unequivocal evidence based upon neuroimaging studies.
bModiﬁed Rankin Score assessments should be made by qualiﬁed individuals
according to a certiﬁcation process. If there is discordance between the 30 and 90
day Modiﬁed Rankin Scores, a ﬁnal determination of major vs. minor stroke will be
adjudicated by the neurology members of the clinical events committee.
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consume major health-care resources. The VARC deﬁnition of
bleeding complications (Table 4) is divided into life-threatening
or disabling bleeding, major bleeding, and minor bleeding; anything
but minor bleeding constitutes a serious or meaningful bleeding
event.
Given the ample body of literature suggesting that administration
of whole blood or red blood cell (RBC) transfusions in patients
with cardiovascular pathology may be potentially harmful,
41–44
VARC considers that any whole blood or RBC transfusion needs
to be reported in the case report forms, including the number
of transfused units, regardless of the presence or absence of
overt bleeding. Transfusions also need to be further stratiﬁed
into those associated with overt bleeding and those in the
absence of overt bleeding. Bleeding complications and transfusions
should also be characterized relative to the time of occurrence
including during the procedure, within the index hospitalization,
or post-discharge.
Acute kidney injury
The natural history of acute kidney injury (AKI) in a variety of clini-
cal settings
61–70 is now well understood, including the recognition
that even small decreases in kidney function can have a dramatic
impact on the risk for subsequent mortality.
69,70 In recent
reports, AKI has been observed in 12–28% of patients undergoing
TAVI and was associated with a four times higher post-procedural
mortality.
71,72
In deﬁning the stages of AKI, VARC proposes adopting serum
creatinine criteria from the ‘modiﬁed’ RIFLE (Risk, Injury, Failure,
Loss, and End-stage kidney disease) classiﬁcation (Table 5).
73 The
RIFLE classiﬁcation
74–76 has been validated in the setting of inten-
sive care units and cardiac surgery
77–81 and provides practical deﬁ-
nitions for early stages of renal dysfunction when kidney injury can
still be prevented, as well as stages when the kidney has already
been damaged and renal failure is established. Modiﬁcations of
the original RIFLE classiﬁcation include two important changes:
(i) smaller changes in serum creatinine (0.3 mg/dL) are included
in stage 1 (‘Risk’)
82; (ii) the ‘Loss’ and ‘End-stage kidney disease’
categories have been removed due to a lack of uniform indications
and timing of renal replacement therapy (RRT) and variability in
RRT resources in different countries. An outer bound of 72 h
from the index procedure for diagnosing AKI was selected based
on evidence that adverse outcomes were observed when the
elevation occurred within 24 to 48 h of the procedure
83 and to
ensure that the process was both acute and related to the pro-
cedure itself rather than as a consequence of post-procedure
multi-organ system failure. Risk, Injury, Failure, Loss, and End-stage
kidney disease classiﬁcations also stress the predictive value of
urine output criteria in deﬁning AKI, but VARC has not included
this measure in the deﬁnition of AKI since urine outputs may
not be measured accurately or routinely in all cases.
Valve Academic Research Consortium proposes to utilize the
modiﬁed RIFLE classiﬁcation to (i) capture even the earliest
stages of AKI (stage 1) on case report forms, (ii) deﬁne AKI as
either stage 2 or 3, and (iii) report any case of RRT (haemodialysis,
peritoneal dialysis, or haemoﬁltration) occurring during the index
hospitalization or within 30 days after the index procedure.
Given the well-recognized damaging impact of contrast media on
renal function, VARC also recommends to report the volume
and type of contrast medium used during the index procedure.
Vascular complications
Recent TAVI literature indicates that major vascular complications
using various non-standardized deﬁnitions (e.g. with or without
including the need for blood transfusions) occur at a frequency
of 4–34% and are associated with a two- or three-fold higher
30-day mortality.
84–87 In deﬁning vascular complications, VARC
referenced the reporting standards of the Society of Vascular
Surgery for deﬁning and reporting vascular complications following
endovascular aortic graft repair procedures.
88
Valve Academic Research Consortium proposes to report both
major and minor vascular complications, but to only consider
major vascular complications as an important clinical endpoint.
Of note, the ‘access site’ is deﬁned as any location (arterial or
venous) traversed by a guide-wire, a catheter or a sheath [including
the left ventricular (LV) apex and the aorta] and ‘access related’ is
deﬁned as any adverse clinical consequence possibly associated
with any of the access sites used during the procedure. The
VARC deﬁnitions for major and minor vascular complications are
described in Table 6.
Many vascular situations require special notice. Femoral vascular
access and closure in many centers is routinely achieved using sur-
gical cut-down procedures, and therefore, pre-planned surgical
access and/or closure should be considered as part of the pro-
cedure and not as a complication. Similarly, uncomplicated non-
femoral (e.g. retroperitoneal, iliac, subclavian, or aortic) surgical
access for sheath entry (planned or unplanned) is not considered
a vascular complication, unless untoward clinical consequences are
documented (e.g. bleeding complications). However, interven-
tional or surgical repair for failed percutaneous closure of the
arteriotomy site during the index procedure without other clinical
sequellae (Table 6) is considered a minor vascular complication.
Considering the recent proliferation of vascular access approaches
and the recognition that speciﬁc access sites and techniques may
be associated with either increased or decreased complications,
................................................................................
Table 5 Acute kidney injury (modiﬁed RIFLE
classiﬁcation)
Change in serum creatinine (up to 72 h) compared with
baseline
Stage 1 Increase in serum creatinine to 150–200% (1.5–
2.0 × increase compared with baseline) or increase of ≥0.3 mg/dL
(≥26.4 mmol/L)
Stage 2 Increase in serum creatinine to 200–300% (2.0–
3.0 × increase compared with baseline) or increase between .0.3
mg/dL (.26.4 mmol/L) and ,4.0 mg/dL (,354 mmol/L)
Stage 3
a Increase in serum creatinine to ≥300% (.3 × increase
compared with baseline) or serum creatinine of ≥4.0 mg/dL (≥354
mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L)
aPatients receiving renal replacement therapy are considered to meet Stage 3
criteria irrespective of other criteria.
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on the access site and technique for each procedure.
A special circumstance relates to complications associated with
the left-ventricular apex site during transapical TAVI procedures.
Although such complications are less frequent than transarterial
vascular complications, a recent report indicates that the clinical
consequences (including death) can be more serious.
89 Major com-
plications associated with transapical TAVI procedures include
bleeding, pseudoaneurysm formation (with or without rupture),
and haemodynamic instability requiring urgent transarterial cardio-
pulmonary bypass support. Valve Academic Research Consortium
proposes that all such complications associated with transapical
TAVI be reported in case report forms and that clinical conse-
quences resulting from such complications be registered under
the appropriate clinical endpoints (e.g. bleeding, stroke, mortality).
Prosthetic valve performance
The clinical presentation of patients with prosthetic valve dysfunc-
tion is usually consistent with symptoms and signs of either valvular
regurgitation or stenosis. Valve Academic Research Consortium
proposes only two criteria to evaluate impaired prosthetic valve
performance: (i) prosthetic valve haemodynamics assessed by
echocardiography and (ii) associated clinical ﬁndings indicating
impaired cardiovascular or valvular function (e.g. new or worsening
congestive heart failure). Transthoracic echocardiography (TTE) is
usually adequate to evaluate prosthetic aortic valve function,
90
although transoesophageal echocardiography (TEE) may be very
useful in the setting of technically challenging or complex cases.
Serial echocardiography evaluations after surgical AVR and TAVI
should be performed at baseline, soon after the index procedure
(ideally within 24–48 h, but always before discharge), at 1
month (especially for TAVI), 12 months, and yearly thereafter.
91,92
This follow-up schedule is more intensive than recommended in
the AHA/ACC and ESC guidelines for follow-up after surgical
AVR,
91,92 but more frequent documentation of valve function
and position is considered desirable for TAVI clinical trials.
Although the VARC deﬁnitions for impaired prosthetic valve
performance discount mechanistic characterizations, valve failure
mode(s) should be recorded whenever possible in case report
forms (Table 7). In addition to echocardiography, multi-slice com-
puted tomography may also provide useful insights into the
responsible patho-biological mechanisms of device
malfunction.
93,94
Prosthetic aortic stenosis and
regurgitation
Utilizing the recent prosthetic valve echocardiography guidelines,
90
the severity of prosthetic aortic valve stenosis is graded as (i)
normal, (ii) possible, or (iii) signiﬁcant (Table 8) and prosthetic
aortic valve regurgitation (central or paravalvular) as (i) mild, (ii)
moderate, or (iii) severe (Table 9). The clinical signiﬁcance of pros-
thetic valve dysfunction is further supported by the presence of
................................................................................
Table 7 Potential failure modes of prosthetic valve
dysfunction
Aortic stenosis
Stent creep
Pannus
Calciﬁcation
Support structure deformation (out-of-round conﬁguration),
under-expansion, fracture, or trauma (cardio-pulmonary
resuscitation, blunt chest trauma)
Mal-sizing (prosthesis-patient mismatch)
Endocarditis
Prosthetic valve thrombosis
Native leaﬂet prolapse impeding prosthetic leaﬂet motion
Aortic regurgitation
Pannus
Calciﬁcation
Support structure deformation (out-of-round conﬁguration), recoil,
under-expansion, fracture, insufﬁcient radial strength, or trauma
(cardio-pulmonary resuscitation, blunt chest trauma)
Endocarditis
Prosthetic valve thrombosis
Malposition (too high, too low)
Acute mal-coaptation
Leaﬂet wear, tear/perforation, prolapse, or retraction
Suture breakage or disruption
Native leaﬂet prolapse impeding prosthetic leaﬂet motion
................................................................................
Table 6 Vascular access site and access-related
complications
Major vascular complications
Any thoracic aortic dissection
Access site or access-related vascular injury (dissection, stenosis,
perforation, rupture, arterio-venous ﬁstula, pseudoaneurysm,
haematoma, irreversible nerve injury, or compartment
syndrome) leading to either death, need for signiﬁcant blood
transfusions (≥4 units), unplanned percutaneous or surgical
intervention, or irreversible end-organ damage (e.g. hypogastric
artery occlusion causing visceral ischaemia or spinal artery injury
causing neurological impairment)
Distal embolization (non-cerebral) from a vascular source requiring
surgery or resulting in amputation or irreversible end-organ
damage
Minor vascular complications
Access site or access-related vascular injury (dissection, stenosis,
perforation, rupture, arterio-venous ﬁstula or pseudoaneuysms
requiring compression or thrombin injection therapy, or
haematomas requiring transfusion of ≥2 but ,4 units) not
requiring unplanned percutaneous or surgical intervention and
not resulting in irreversible end-organ damage
Distal embolization treated with embolectomy and/or
thrombectomy and not resulting in amputation or irreversible
end-organ damage
Failure of percutaneous access site closure resulting in
interventional (e.g. stent-graft) or surgical correction and not
associated with death, need for signiﬁcant blood transfusions
(≥4 units), or irreversible end-organ damage
VARC consensus endpoints after TAVI for high risk AS 211clinical signs, symptoms, and/or events (e.g. re-hospitalization for
worsening symptoms, re-operation or death).
Transcatheter aortic valve implantation devices are associated
with a higher frequency of mild and moderate paravalvular aortic
regurgitation (AR) than surgical AVR.
95–107 There is a need to
develop improved deﬁnitions and to better understand the long-
term clinical implications of paravalvular prosthetic AR. Unfortu-
nately, the precise grading of paravalvular AR remains controversial
and many echocardiography experts believe that grading schemes
for prosthetic central and paravalvular AR should be differ-
ent.
90,108–111 Recently, in the setting of TAVI, criteria for assessing
paravalvular AR severity have emphasized a ‘jet anatomy’ classiﬁ-
cation, stressing the location, circumferential extent, and width of
the AR jet.
90 Haemodynamic factors can also be useful to assess
the AR severity immediately after valve implantation (e.g. loss of
aortic dicrotic notch, equalization of end-diastolic aortic and left
ventricular pressures). Since there is lack of clarity concerning
the long-term clinical implications of mild and moderate paravalv-
ular AR after TAVI, echocardiography core laboratories are useful
to ensure consistent evaluation methods. Echocardiograms should
be performed annually in those patients known to have post-
procedural paravalvular AR.
Prosthetic aortic valve thrombosis and
endocarditis
Although prosthetic valve thrombosis and prosthetic valve endo-
carditis have been included as potential failure modes for prosthe-
tic valve dysfunction (Table 7), they require reporting as individual
endpoints. Valve thrombosis is any thrombus attached to or near
an implanted valve that occludes part of the blood ﬂow path, inter-
feres with valve function, or is sufﬁciently large to warrant treat-
ment.
12 Furthermore, valve thrombus found at autopsy in a
patient whose cause of death was not valve related or found at
operation for an unrelated indication should also be reported as
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 9 Prosthetic aortic valve regurgitation criteria (central and paravalvular)
Parameter Mild Moderate Severe
Valve structure and motion
Mechanical or bioprosthetic Usually normal Usually abnormal Usually abnormal
Structural parameters
Left ventricular size Normal Normal/mildly dilated Dilated
Doppler parameters (qualitative or semi-quantitative)
Jet width in central jets (% LVO diameter): color
a Narrow (≤25%) Intermediate (26–64%) Large (≥65%)
Jet density: CW Doppler Incomplete or faint Dense Dense
Jet deceleration rate (PHT, ms): CW Doppler
b Slow (.500) Variable (200–500) Steep (,200)
LV outﬂow vs. pulmonary ﬂow: PW Doppler Slightly increased Intermediate Greatly increased
Diastolic ﬂow reversal in the descending aorta:
PW Doppler Absent or brief early diastolic Intermediate Prominent, holodiastolic
Circumferential extent of paraprosthetic AR (%)
c ,10 10–20 .20
Doppler parameters (quantitative)
Regurgitant volume (mL/beat) ,30 30–59 .60
Regurgitant fraction (%) ,30 30–50 .50
aParameter applicable to central jets and is less accurate in eccentric jets.
bInﬂuenced by left ventricular compliance.
cFor paravalvular aortic regurgitation.
AR, aortic regurgitation; CW, continuous wave; LVO, left ventricular outﬂow; PW, pulsed wave.
...............................................................................................................................................................................
Table 8 Prosthetic aortic valve stenosis criteria
a
Parameter Normal Possible stenosis Signiﬁcant stenosis
Peak velocity (m/s)
b ,33 – 4 .4
Mean gradient (mmHg)
b ,20 20–35 .35
Doppler velocity index ≥0.30 0.29–0.25 ,0.25
Effective oriﬁce area (cm
2) .1.2 1.2–0.8 ,0.80
Contour of the jet velocity through the prosthetic valve Triangular, early peaking Triangular to intermediate Rounded, symmetrical contour
Acceleration time (ms) ,80 80–100 .100
aIn conditions of normal or near normal stroke volume (50–70 mL).
bThese parameters are more affected by ﬂow, including concomitant aortic regurgitation.
M.B. Leon et al. 212valve thrombosis. The diagnosis of prosthetic valve thrombosis is
best discerned during an echocardiographical examination or
during surgical exploration. There have already been case
reports and anecdotes
112 of transcatheter prosthetic valve throm-
bosis with and without important clinical consequences.
The diagnosis of prosthetic valve endocarditis is based on one of
the following criteria
12:
† reoperation with evidence of abscess, paravalvular leak, pus, or
vegetation conﬁrmed as secondary to infection by histological
or bacteriological studies;
† autopsy ﬁndings of abscess, pus, or vegetation involving a
repaired or replaced valve;
† in the absence of reoperation or autopsy, fulﬁling the Duke Cri-
teria for endocarditis.
113
Isolated case reports of transcatheter aortic valve endocarditis have
alreadybeenpublished.
114,115Owingtothevariabilityintranscatheter
valve designs and positioning within the aortic root, meticulous
reporting of the pattern of endocarditis is mandatory.
116
Prosthetic valve ‘associated’
complications
Depending on the design characteristics and ﬁnal implant position,
prosthetic aortic valves may come in close contact with the anterior
mitral valve leaﬂet, the intervalvular ﬁbrosa, the aortic annulus, the
ventricular septum, the aortic sinuses and root, the coronary
arteries, and the cardiac conduction system. Collectively, these ana-
tomic structures, which are contiguous with the prosthetic aortic
valve, are referred to as the aortic valvar complex (Figure 2). As
such, prosthetic aortic valve procedures, and in particular TAVI,
may have untoward effects on any of these structures which may
result in important clinical consequences. Therefore, VARC
proposes to group these complications as a separate endpoint cat-
egory. However, it must be noted, that some of these adverse
events may not be directly related to The Valve prosthesis itself,
but may occur before or after valve implantation (e.g. conduction
disturbances after pre-implant balloon aortic valvuloplasty).
Conduction disturbances and cardiac
arrhythmias
The close anatomical relationship between the aortic valvar
complex and the branching atrioventricular bundle explains the
possible development of conduction abnormalities following pros-
thetic aortic valve procedures.
117,118 Following surgical AVR, new-
onset bundle branch block has been reported in 16–32% of
patients and the need for permanent pacemakers in 3–8% of
patients.
119–123 In early experiences with TAVI, new-onset
bundle branch block has occurred in up to 45% of patients and
the need for permanent pacemakers has varied from as low as
4% to as high as 33%.
95–98,124–128 Differences among devices
and heterogeneity in physician and country-based healthcare
thresholds may explain the signiﬁcant inter-hospital variability in
new permanent pacemaker requirements after TAVI.
Although the implications of persistent left bundle branch block
(LBBB) after TAVI are currently unknown, the presence of new
bundle branch block after surgical AVR has been associated
with increased risk of subsequent arrhythmic events during
follow-up (speciﬁcally, syncope, AV dissociation, and sudden
death).
119,120 Owing to this association between conduction
system abnormalities and adverse patient outcomes following sur-
gical AVR and several anecdotal reports after TAVI of either early
post-discharge severe bradyarrhythmic events or sudden cardiac
death,
15 VARC recommends to carefully document the occur-
rence of new conduction system abnormalities (left bundle
branch block and third degree atrioventricular block), as well as
the requirements and indications for new permanent pacemakers
within 30 days after the procedure. The timing (days) and location
(intra-procedural, in-hospital, or post-discharge) of the event
should also be recorded. To accurately capture such events,
daily ECGs and continuous telemetry ECG monitoring should
be considered while the patients are in-hospital, and should be
required in patients with any evidence of new conduction
abnormalities or arrhythmias.
Although conduction abnormalities associated with TAVI have
been a recent concern, it bears noting that new onset atrial ﬁbrilla-
tion and ventricular arrhythmias have also been observed after
both TAVI and surgical AVR procedures.
128 In particular, new
onset atrial ﬁbrillation occurs in as many as 20–30% of patients
after conventional surgical AVR
129,130 and any valid comparison
of transcatheter vs. surgical aortic valve treatment strategies
should include a careful analysis of post-therapy supra-ventricular
and ventricular arrhythmias.
Coronary obstruction
Mechanical coronary artery obstruction following TAVI or surgical
AVR is rare and occurs in ,1% of patients.
96,97 The obstruction
typically occurs during the index procedure. Importantly, clinical
signs and symptoms may be subtle and not appreciated until
Figure 2 The aortic valvar complex, including the aortic valve,
annulus, sinuses, aorta, coronary arteries, membranous septum,
and the mitral valve.
VARC consensus endpoints after TAVI for high risk AS 213after the procedure. Possible mechanisms for mechanical coronary
obstruction include (i) impingement of the coronary ostia by The
Valve support structure in the setting of suboptimal valve position-
ing and/or ‘small aortic root’ anatomy; (ii) embolization from
calcium, thrombus, air, or endocarditis; (iii) displacement of
native aortic valve leaﬂets towards the coronary ostia during
TAVI,
131,132 and (iv) suture-related kinking or obstruction or
cannulation-related obstruction of the coronary ostia associated
with surgical AVR.
The diagnosis of TAVI-associated coronary obstruction can be
determined by imaging studies (coronary angiography, intravascular
ultrasound, multi-slice CT angiography, or echocardiography), sur-
gical exploration, or autopsy ﬁndings. Cardiac biomarker elevations
and ECG changes indicating new ischaemia provide corroborative
evidence.
Other prosthesis-related adverse events
The short- and long-term consequences of contact, trauma, or
impingement on the anterior mitral valve leaﬂet by the ventricular
end of a transcatheter aortic valve are currently unknown. Never-
theless, any new mitral valve dysfunction (e.g. worsening mitral
regurgitation or stenosis) or disruption (e.g. chordal rupture,
leaﬂet perforation, anterior mitral valve leaﬂet aneurysm) related
to contact with the transcatheter valve implant or mitral valve
endocarditis
114–116 should be carefully documented. Other infre-
quent complications following TAVI include new ventricular
septal defects and aortic root rupture/perforation/dissection,
occurring either during the pre-implant balloon aortic valvulo-
plasty, or during the transcatheter valve implant.
133,134
Clinical beneﬁt endpoints
In addition to the avoidance of mortality, speciﬁc endpoints to
establish the clinical beneﬁt after TAVI are important. Objective
beneﬁt parameters derived from the heart failure literature can
be adapted in valve-related clinical trials.
135 Several choices are
available, including exercise performance,
136 assessment of
New York Heart Association (NYHA) functional status,
137 and
various quality of life
138 and frailty questionnaires.
139 Each of
these symptom evaluation tools has strengths and weaknesses in
the TAVI patient population, which is disproportionately rep-
resented by elderly, frail, individuals with multiple co-morbidities.
For instance, exercise test performance is an appealing endpoint,
but as aortic valve therapy studies are unblinded, they may be
biased and they can be difﬁcult to perform in high-risk TAVI
patients.
Valve Academic Research Consortium has also considered a cat-
egorical endpoint of clinical beneﬁt which captures failure of
current AS therapy; hospitalization for symptoms of cardiac or
valve-related decompensation, at least 30 days after the index pro-
cedure (surgical AVR or TAVI). This endpoint mandates careful
adjudication by a clinical events committee and is deﬁned as hos-
pitalization for symptoms of valve or cardiac deterioration (e.g.
new or worsening heart failure, angina, or syncope) requiring
either a valve procedure (surgery or interventional treatment) or
intensiﬁcation of medical management (new or increased use of
inotropes, vasopressors, diuretics, and/or vasodilators).
Quality-of-life and healthcare economic instruments can be
useful to assess disability and impairment due to congestive
heart failure (e.g. Kansas City Cardiomyopathy Questionnaire)
140
and for mapping health status compared with population-level
utility weights (e.g. EuroQOL questionnaire).
141–143 However,
quality-of-life questionnaires are also prone to bias and must be
uniformly administered. The time points for assessment of the
aforementioned clinical beneﬁt endpoints should be at 30 days,
at 6 months, and at 1 year after initiating therapy. Valve Academic
Research Consortium recommends that if any measure of clinical
beneﬁt is utilized in clinical trials, there must be careful oversight
and adjudication by experienced clinical events committees.
The assessment of ‘frailty’ in patients with advanced valvular
heart disease has become increasingly important and is usually
not included in surgical-risk algorithms. Frailty is loosely deﬁned
as a biological syndrome of decreased reserve and resistance to
stressors, resulting from cumulative declines across multiple phys-
iological systems, and causing vulnerability to adverse outcomes.
139
Various frailty indices have been developed and have been corre-
lated with worsening clinical outcomes in geriatric patients in
intensive care units and after surgery.
144–146 In general, the evalu-
ation of frailty demands a composite analysis of several categorical
and continuous variables including mobility, strength, endurance,
activities of daily living, cognitive impairment, and nutritional
status (as discerned by body mass index and biomarkers such as
serum albumin).
147,148 Although there is no standard frailty index
which has been applied and validated in high-risk AS patients, mul-
tiple preliminary efforts are ongoing and VARC proposes to
include measures of frailty in future clinical trials as a component
of clinical beneﬁt endpoints.
Therapy-speciﬁc endpoints
Given the complex nature of TAVI procedures and the rapid evol-
ution of devices and procedural techniques, VARC proposes to
record in case report forms (but not as formal endpoints) an
open category of therapy-speciﬁc endpoints which may be relevant
to clinical outcomes or device performance. Examples of such
events include the following: (i) the unplanned use of cardio-
pulmonary bypass to manage haemodynamic compromise or to
reverse procedural complications; (ii) conversion from a ‘failed’
percutaneous transcatheter procedure to an ‘open’ surgical AVR
or to a surgical-access TAVI
149,150; (iii) ventricular perforation
(for any reason) with and without cardiac tamponade
151; (iv) pros-
thetic valve migration or dislocation from the native aortic valve
landing zone
152,153; (v) frequency, reasons, and results of post-TAVI
balloon dilation; (vi) frequency, reasons, and results after place-
ment of a second valve over the original valve, so-called TAVI
‘valve-in-valve’
154,155; (vii) integrity of the support structure, includ-
ing strut fractures, compression or other evidence of geometry dis-
tortion (requires careful serial imaging modalities including
cine-ﬂuoroscopic analyses and echocardiography)
90,156–158; (viii)
instances of device recapture (with or without repositioning), or
retrieval (removal from the body) which occur during the index
procedure; (ix) re-intervention (either percutaneous or surgical)
for any reason after the index procedure.
159 As appropriate, the
timing of these events (during the index procedure, in-hospital,
M.B. Leon et al. 214or post-discharge) should be carefully recorded. This category is
intended to be a dynamic platform and should be added to the
case report forms.
Clinically relevant composite
endpoints
Although VARC discourages the overuse of composite endpoints,
to achieve overall impressions of safety and effectiveness may
require the incorporation of more than single endpoints. These
strategic assessments of TAVI as an alternative therapy should
ideally include device, procedure, and patient-oriented factors.
Valve Academic Research Consortium proposes three composite
endpoints (Table 10): device success (intra-procedure), a combined
safety endpoint (at 30 days), and a combined efﬁcacy endpoint (at
1 year or longer).
Device success is a ‘technical’ composite endpoint meant to
characterize the acute device and procedural factors which
underlie vascular access, delivery, and performance of the TAVI
system. Echocardiography should be routinely utilized as the stan-
dard for measuring prosthetic valve stenosis and regurgitation
immediately after TAVI, and should always be performed in a
resting state, either within 24–48 h after the index procedure or
before hospital discharge.
The 30-day combined safety endpoint is a hierarchical composite
of the most relevant patient-oriented safety endpoints previously
deﬁned by VARC (Table 10). In addition, a repeat procedure in
the ﬁrst 30 days (either surgery or intervention) to treat
valve-related dysfunction is also incorporated in this endpoint.
Examples of urgent repeat procedures would include balloon
aortic valvuloplasty or repeat TAVI (valve-in-valve) to treat
either paravalvular or central severe AR after the TAVI. The
focus on 30-day events after the index procedure is meant to
isolate safety concerns largely pertaining to early device perform-
ance and the procedure. Nonetheless, overall patient safety also
requires a careful examination of pertinent individual safety end-
points over the life history of the device.
The time-sensitive assessment of TAVI effectiveness requires a
more delayed combined efﬁcacy endpoint incorporating major clini-
cal and valve performance factors. Valve Academic Research Con-
sortium proposes a 1-year (or longer) time interval for the
combined efﬁcacy endpoint integrating three important endpoints:
(i) all-cause mortality after 30 days, meant to reﬂect therapy effec-
tiveness by measuring prevention of AS-related mortality over
time; (ii) failure of the current therapy for AS, requiring hospitaliz-
ation for symptoms of valve-related or cardiac decompensation
(adjudicated episodes of heart failure, angina, or syncope requiring
an aortic valve procedure or intensiﬁcation of medical manage-
ment); (iii) evidence of prosthetic valve dysfunction, deﬁned
using strict echocardiography criteria, possibly in conjunction
with other signs of functional deterioration.
Discussion
The VARC was convened in response to an urgent call for standar-
dized clinical research processes involving the emerging ﬁeld of
transcatheter valve therapies, and more speciﬁcally, TAVI in
high-surgical-risk patients with AS. The inter-disciplinary nature
of TAVI, combining aspects of both surgical and interventional
therapies, presented special challenges and required an enlightened
and collaborative approach to the development of clinical research
recommendations and endpoint deﬁnitions.
160,161 The VARC
initiative is an attempt to achieve a necessary consensus among
the various subspecialties and stakeholders, such that this innova-
tive treatment strategy may be evaluated objectively and according
to a set of practical endpoint deﬁnitions.
This consensus manuscript is not intended to be interpreted as
a ‘guidelines’ or ‘guidance’ document and although thoroughly
reviewed by individuals from seven cardiology and cardiac surgery
societies, the content has not been subjected to a formal society
guidelines review process. These standardized endpoints are mea-
sureable, apply to both predicate surgical and new transcatheter
therapies, can be adjudicated by clinical events committees, and
can be used to compare ﬁndings from different clinical trials. By
intent, this consensus manuscript was not device-speciﬁc and the
deﬁnitions can be applied to next generation and iterative TAVI
devices already under early stages of clinical investigation.
162–165
Given the rapid growth in transcatheter valve therapies, and the
potential exposure of this technology to lower risk patient popu-
lations, it is certain that this preliminary attempt to arrive at con-
sensus endpoint deﬁnitions for TAVI will need reﬁnement in the
future. In principle, the consensus process calls for the highest
standards of clinical research, including (i) inter-disciplinary
experts gathering to arrive at standardized endpoint deﬁnitions,
................................................................................
................................................................................
Table 10 Composite endpoints
Device success
Successful vascular access, delivery and deployment of the device
and successful retrieval of the delivery system
Correct position of the device in the proper anatomical location
Intended performance of the prosthetic heart valve (aortic valve
area .1.2 cm
2 and mean aortic valve gradient ,20 mmHg or
peak velocity ,3 m/s, without moderate or severe prosthetic
valve AR)
Only one valve implanted in the proper anatomical location
Combined safety endpoint (at 30 days)
All-cause mortality
Major stroke
Life-threatening (or disabling) bleeding
Acute kidney injury—Stage 3 (including renal replacement therapy)
Peri-procedural MI
Major vascular complication
Repeat procedure for valve-related dysfunction (surgical or
interventional therapy)
Combined efﬁcacy endpoint (at 1 year or longer)
All-cause mortality (after 30 days)
Failure of current therapy for AS, requiring hospitalization for
symptoms of valve-related or cardiac decompensation
Prosthetic heart valve dysfunction (aortic valve area ,1.2 cm
2 and
mean aortic valve gradient ≥20 mmHg or peak velocity ≥3 m/s,
OR moderate or severe prosthetic valve AR)
VARC consensus endpoints after TAVI for high risk AS 215(ii) harmonized and well-structured data collection, interpretation,
and reporting for speciﬁc TAVI-related clinical events, and (iii) the
consistent use of central core laboratories and independent,
blinded endpoint adjudication.
Many of the endpoints discussed in this manuscript are sufﬁ-
ciently general that they can be applied to other AS populations
and to other valvular heart disease clinical research scenarios,
both surgical and interventional. This is particularly germane to
TAVI clinical research, as new studies involving lower risk AS
patients are already being considered. Importantly, recent
reports and randomized trials using new catheter-based mitral
valve therapies to treat mitral regurgitation
166–168 also suffer
from non-standardized endpoint deﬁnitions and might well
beneﬁt from a comparable VARC consensus effort.
This consensus manuscript, which represents the ‘ﬁrst step’ in a
much longer road to help improve clinical research in valvular
heart disease, has several limitations. The endpoint deﬁnitions
were intended to be reasonably broad, but nonetheless in some
instances are also intentionally narrow to address the speciﬁc con-
siderations of TAVI in high-surgical-risk patients with severe AS.
Therefore, application of all of these endpoint deﬁnitions to
other patient populations may be problematic. The important
area of pre-clinical device testing, both assessments of valve and
support structure properties and in vivo animal studies, is beyond
the scope of this manuscript. Other aspects of clinical trial
design and clinical trial methodologies are also essential to opti-
mize clinical research, but similarly, a comprehensive treatment
of these subjects could not be included in this manuscript.
Finally, many global endpoints, such as stroke and bleeding and
some speciﬁc endpoints, such as paravalvular regurgitation, are
themselves in a state of evolution, subject to modiﬁcations by
other consensus committees in the near future.
The VARC process embodied in this manuscript was an ambi-
tious multi-disciplinary attempt to bring order through consensus,
thereby providing standardization of clinical research in the bur-
geoning area of transcatheter aortic valve therapy. Hopefully, this
template can also serve as a model to improve clinical research
methodologies in the evaluation of new therapies for other cardio-
vascular diseases.
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endpoint requirements after TAVI
† Mortality (all cause and cardiovascular)
† Myocardial Infarction (peri-procedural and spontaneous)
† Stroke (major and minor)
† Bleeding (life threatening or disabling and major)
† Acute kidney injury (modiﬁed RIFLE stage 2 and 3, including
RRT)
† Vascular complications (major)
† Prosthetic valve performance (requires serial echocardiography
assessments)
(a) Prosthetic valve stenosis (possible and signiﬁcant) and
regurgitation (moderate or severe with special reference
to paravalvular regurgitation)
(b) Prosthetic valve thrombosis
(c) Prosthetic valve endocarditis
† Prosthetic valve-associated complications
(a) Conduction disturbances and cardiac arrhythmias (including
new LBBB, new permanent pacemaker implantation, and
new supra-ventricular or ventricular arrhythmias) and
(b) Coronary obstruction
† Clinical beneﬁt endpoints
(a) Symptom status (global assessments using NHYA classiﬁ-
cation and some measure of quality of life)
(b) Repeat hospitalization (.30 days after the index pro-
cedure) for valve-related or cardiac decompensation)
† Therapy speciﬁc endpoints (ventricular perforation at any time
resulting in cardiac tamponade, prosthetic valve embolization,
and acute or delayed valve-in-valve treatment)
† Composite endpoints
(a) Device success
(b) Combined safety endpoint (at 30 days)
(c) Combined efﬁcacy endpoint (at 1 year or longer)
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